Cargando…
Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro
Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A n...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653589/ https://www.ncbi.nlm.nih.gov/pubmed/36365509 http://dx.doi.org/10.3390/polym14214515 |
_version_ | 1784828717270302720 |
---|---|
author | Xu, Jiankun Lin, Shanmeng Hu, Hao Xing, Qi Geng, Jin |
author_facet | Xu, Jiankun Lin, Shanmeng Hu, Hao Xing, Qi Geng, Jin |
author_sort | Xu, Jiankun |
collection | PubMed |
description | Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A novel water-soluble polymer–drug conjugate with buf and fluorescein pendants was prepared by the combination of reversible addition-fragmentation transfer (RAFT) polymerization and click chemistry. Its anticancer performance and cellular uptake behavior against liver cancer were investigated in vitro. The polymer–buf conjugates exhibit controlled release and tumor-targeting capabilities, showing promise for clinical applications. |
format | Online Article Text |
id | pubmed-9653589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96535892022-11-15 Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro Xu, Jiankun Lin, Shanmeng Hu, Hao Xing, Qi Geng, Jin Polymers (Basel) Article Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A novel water-soluble polymer–drug conjugate with buf and fluorescein pendants was prepared by the combination of reversible addition-fragmentation transfer (RAFT) polymerization and click chemistry. Its anticancer performance and cellular uptake behavior against liver cancer were investigated in vitro. The polymer–buf conjugates exhibit controlled release and tumor-targeting capabilities, showing promise for clinical applications. MDPI 2022-10-25 /pmc/articles/PMC9653589/ /pubmed/36365509 http://dx.doi.org/10.3390/polym14214515 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xu, Jiankun Lin, Shanmeng Hu, Hao Xing, Qi Geng, Jin Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro |
title | Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro |
title_full | Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro |
title_fullStr | Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro |
title_full_unstemmed | Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro |
title_short | Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro |
title_sort | tumor-targeting polymer–drug conjugate for liver cancer treatment in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653589/ https://www.ncbi.nlm.nih.gov/pubmed/36365509 http://dx.doi.org/10.3390/polym14214515 |
work_keys_str_mv | AT xujiankun tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro AT linshanmeng tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro AT huhao tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro AT xingqi tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro AT gengjin tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro |